Sudhir Agrawal
Sudhir Agrawal has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
- Cara Haymaker
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
11 shared publications - Chantale Bernatchez
The University of Texas MD Anderson Cancer Center, Houston, Texas
11 shared publications - Marc Isamu Uemura
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
11 shared publications Marihella James
11 shared publications- Michael A. Davies
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
11 shared publications - Courtney W. Hudgens
The University of Texas MD Anderson Cancer Center
10 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (40) , 60497-60504
From a Concept on a Chalkboard to Gapmer Antisense
Gapmer antisense oligonucleotides emerged from our efforts to improve the stability, affinity, and potency of early phosphodiester and phosphorothioate (PS) antisense oligonucleotides. Working with Paul Zamecnik during the late 1980s and early 1990s, I witnessed the transition from a simple steric-block model of antisense action to the recognition of RNase H as the central driver of potency. Our systematic exploration of backbone and sugar modifications revealed the limitations of single-chemistry approaches and led to the development of hybrid antisense constructs that combined deoxyribonucleotide with 2′-modified ribonucleotide segments, all PS-modified. Such designs later became known as gapmers and provided enhanced stability, improved affinity, and efficient RNase H activation. Although our initial efforts with phosphorothioate oligonucleotides faltered in the clinic, continued refinement of the hybrid designs ultimately enabled the development of multiple approved drugs. Here I describe how a concept sketched on a chalkboard evolved into a widely adopted therapeutic platform.
- 29 September 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (40) , 60497-60504
Open AccessFrom a Concept on a Chalkboard to Gapmer Antisense
Gapmer antisense oligonucleotides emerged from our efforts to improve the stability, affinity, and potency of early phosphodiester and phosphorothioate (PS) antisense oligonucleotides. Working with Paul Zamecnik during the late 1980s and early 1990s, I witnessed the transition from a simple steric-block model of antisense action to the recognition of RNase H as the central driver of potency. Our systematic exploration of backbone and sugar modifications revealed the limitations of single-chemistry approaches and led to the development of hybrid antisense constructs that combined deoxyribonucleotide with 2′-modified ribonucleotide segments, all PS-modified. Such designs later became known as gapmers and provided enhanced stability, improved affinity, and efficient RNase H activation. Although our initial efforts with phosphorothioate oligonucleotides faltered in the clinic, continued refinement of the hybrid designs ultimately enabled the development of multiple approved drugs. Here I describe how a concept sketched on a chalkboard evolved into a widely adopted therapeutic platform.
- Open Access
- 21 July 2026
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 37 (3)
Development of an antisense oligonucleotide targeting EFEMP1 in models relevant to macular degeneration
- 21 July 2026
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 37 (3)
Open AccessDevelopment of an antisense oligonucleotide targeting EFEMP1 in models relevant to macular degeneration
- 12 February 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (2) , 61
Proceedings of the 2024 FDA-CRCG Workshop: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products
On Oct 7 and 8, 2024, the US Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG) co-hosted a workshop titled “S
- 12 February 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (2) , 61
Proceedings of the 2024 FDA-CRCG Workshop: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products
On Oct 7 and 8, 2024, the US Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG) co-hosted a workshop titled “S
- Open Access
- 30 January 2026
- Published by Wiley in Current Protocols
- Vol. 6 (2) , e70319
Transient Cyclic Structured Oligonucleotide Designs for Therapeutic Applications
Oligonucleotide‐based therapeutics are now widely used in clinical settings. From the late 1980s to the mid‐1990s, efforts to improve therapeutic efficacy focused on imparting drug‐like properties to oligonucleotides, emphasizing nuclease stability and target sequence affinity. These efforts resulted in the standard gapmer design for RNase H–mediated antisense and the prevalent use of chemical modification such as phosphorothioate and 2′‐substituted oligoribonucleotides in oligonucleotide therapeutics. Progress made in the antisense field also enabled the development of splice‐modulating oligonucleotide therapeutics and later siRNA therapies. All three modes of action are now widely employed in >25 approved drugs. Since then, we have learned that oligonucleotides and their chemical modifications can interact with pattern recognition receptors as well as various other proteins. This can have both positive and negative effects, such as aiding in oligonucleotide delivery or activating the intracellular innate immune system. My current work aims to optimize the drug‐like properties of oligonucleotides by combining the early chemical advances with the more recent insights into off‐target protein binding. The present article describes how this resulted in several different cyclic structured oligonucleotide designs, in which 3′ and 5′ ends are transiently held together via Watson‐Crick base pairing. The transient nature of these cyclic structures protects the functional parts of the structure against nucleases during delivery and cell entry while allowing effective release of the oligonucleotide drug into the intracellular environment. These cyclic designs demonstrate significant improvements in potency and specificity over gapmer antisense and are broadly applicable to potentially all types of RNA therapeutics, irrespective of their mechanism of action. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC.
- 30 January 2026
- Published by Wiley in Current Protocols
- Vol. 6 (2) , e70319
Open AccessTransient Cyclic Structured Oligonucleotide Designs for Therapeutic Applications
Oligonucleotide‐based therapeutics are now widely used in clinical settings. From the late 1980s to the mid‐1990s, efforts to improve therapeutic efficacy focused on imparting drug‐like properties to oligonucleotides, emphasizing nuclease stability and target sequence affinity. These efforts resulted in the standard gapmer design for RNase H–mediated antisense and the prevalent use of chemical modification such as phosphorothioate and 2′‐substituted oligoribonucleotides in oligonucleotide therapeutics. Progress made in the antisense field also enabled the development of splice‐modulating oligonucleotide therapeutics and later siRNA therapies. All three modes of action are now widely employed in >25 approved drugs. Since then, we have learned that oligonucleotides and their chemical modifications can interact with pattern recognition receptors as well as various other proteins. This can have both positive and negative effects, such as aiding in oligonucleotide delivery or activating the intracellular innate immune system. My current work aims to optimize the drug‐like properties of oligonucleotides by combining the early chemical advances with the more recent insights into off‐target protein binding. The present article describes how this resulted in several different cyclic structured oligonucleotide designs, in which 3′ and 5′ ends are transiently held together via Watson‐Crick base pairing. The transient nature of these cyclic structures protects the functional parts of the structure against nucleases during delivery and cell entry while allowing effective release of the oligonucleotide drug into the intracellular environment. These cyclic designs demonstrate significant improvements in potency and specificity over gapmer antisense and are broadly applicable to potentially all types of RNA therapeutics, irrespective of their mechanism of action. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
Supplementary Data from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
Supplementary Data from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
Many patients with advanced melanoma are resistant to immune checkpoint inhibition. In the ILLUMINATE-204 phase I/II trial, we assessed intratumoral tilsotolimod, an investigational Toll-like receptor 9 agonist, with systemic ipilimumab in patients with anti–PD-1– resistant advanced melanoma. In all patients, 48.4% experienced grade 3/4 treatment-emergent adverse events. The overall response rate at the recommended phase II dose of 8 mg was 22.4%, and an additional 49% of patients had stable disease. Responses in noninjected lesions and in patients expected to be resistant to ipilimumab monotherapy were observed. Rapid induction of a local IFNα gene signature, dendritic cell maturation and enhanced markers of antigen presentation, and T-cell clonal expansion correlated with clinical response. A phase III clinical trial with this combination (NCT03445533) is ongoing.Significance:Despite recent developments in advanced melanoma therapies, most patients do not experience durable responses. Intratumoral tilsotolimod injection elicits a rapid, local type 1 IFN response and, in combination with ipilimumab, activates T cells to promote clinical activity, including in distant lesions and patients not expected to respond to ipilimumab alone.This article is highlighted in the In This Issue feature, p. 1861
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
Many patients with advanced melanoma are resistant to immune checkpoint inhibition. In the ILLUMINATE-204 phase I/II trial, we assessed intratumoral tilsotolimod, an investigational Toll-like receptor 9 agonist, with systemic ipilimumab in patients with anti–PD-1– resistant advanced melanoma. In all patients, 48.4% experienced grade 3/4 treatment-emergent adverse events. The overall response rate at the recommended phase II dose of 8 mg was 22.4%, and an additional 49% of patients had stable disease. Responses in noninjected lesions and in patients expected to be resistant to ipilimumab monotherapy were observed. Rapid induction of a local IFNα gene signature, dendritic cell maturation and enhanced markers of antigen presentation, and T-cell clonal expansion correlated with clinical response. A phase III clinical trial with this combination (NCT03445533) is ongoing.Significance:Despite recent developments in advanced melanoma therapies, most patients do not experience durable responses. Intratumoral tilsotolimod injection elicits a rapid, local type 1 IFN response and, in combination with ipilimumab, activates T cells to promote clinical activity, including in distant lesions and patients not expected to respond to ipilimumab alone.This article is highlighted in the In This Issue feature, p. 1861
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma